Compare Lululemon Athletica Inc (LULU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Lululemon Athletica Inc trades at $94.64 (market cap $10.27B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: Lululemon Athletica Inc and State Street SPDR S&P Biotech ETF are close in size by market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Lululemon Athletica Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lululemon Athletica Inc for 105 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| LULU | XBI | |
|---|---|---|
Market Cap | $10.27B | $10.11B |
Volume | 4,392,324 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $215.88 | $169.55 |
52-Week Low | $91.88 | $104.99 |
Typical Hold Time | 105 Days | 38 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon stock trades at $94.21, down 54% year-to-date and near its 52-week low. Despite strong profitability with a 56.11% gross margin and 30.9% ROE, recent revenue declines and a bearish technical signal have pressured shares. Multiple law firms are investigating potential securities fraud following the stock's sharp drop, while earnings have consistently beaten expectations.
The outlook remains challenged by growth concerns and governance scrutiny, though a low P/E of 7.63 offers valuation support. Risks include competitive pressures and ongoing legal probes, but analyst consensus targets $97.67, suggesting moderate upside if execution improves.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
